Skip to main content

Table 3 Bivariate analysis of variables collected on D1 influencing the outcome, at ICU discharge, of pneumococcal CAP*

From: Severe pneumococcal pneumonia: impact of new quinolones on prognosis

Variables Survivors n = 44 Non survivors n = 26 p
Age > 70 yrs. 14 (31.8%) 16 (61.6%) 0.01
Gender: Male/Female 33/11 20/6 0.85
Malignancy 4 (9.0%) 1 (3.8%) 0.41
Diabetes mellitus 7 (15.5%) 4 (15.4%) 0.95
Chronic heart failure 4 (9.1%) 7 (26.9%) 0.04
Chronic respiratory insufficiency 8 (18.2%) 4 (15.4%) 0.76
Immunosuppression 10 (22.7%) 3 (11.5%) 0.24
SAPS II >50 18 (40.1%) 19 (73.1%) 0.009
LOD >8 13 (29.5%) 16 (61.6%) 0.008
SOFA >8 14 (31.8%) 18 (69.3%) 0.002
PSI 4/5 17/27 4/22 0.04
MV on D1 32 (72.7%) 23 (88.4%) 0.12
Septic shock 14 (31.8%) 20 (76.9%) 0.0003
Bacteremia 14 (31.8%) 11 (42.3%) 0.37
Patients in Group A/Group B 21/23 17/9 0.15
Cephalosporin in initial treatment 30 (68.2%) 16 (61.6%) 0.57
  1. *Data are presented as No. (%)
  2. MV: mechanical ventilation; SAPS: simplified acute physiology score; LOD score: logistic organ dysfunction score: SOFA: Sepsis-related Organ Failure Assessment score; PSI: Pneumonia Severity Index.